Total Voting Rights

RNS Number : 0773B

Oxford Biomedica PLC

04 June 2019

 

Oxford Biomedica

Completion of Subscription and Total Voting Rights

Oxford, UK - 4 June 2019: Oxford Biomedica plc ("Oxford Biomedica" or "the Company") (LSE: OXB), announces that further to the announcement made on 29 May 2019 regarding Novo Holdings having exercised the option under the Subscription Agreement, the Company confirms that following admission to trading of the 1,181,976 Further Shares this morning and also 312 shares issued following exercise of options, that its issued share capital now consists of 76,738,168 ordinary shares of 50p each. There are no Ordinary Shares held in treasury.

Accordingly, the total number of voting rights in Oxford Biomedica plc at the date of this notice is 76,738,168.

The above figure (76,738,168) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford Biomedica plc under the FCA's Disclosure Guidance and Transparency Rules.

Where undefined, all capitalised terms in this announcement will have the same meaning as defined in the Strategic Investment by Novo Holdings A/S announcement published on 28 May 2019.

-Ends-

For further information, please contact:
Oxford Biomedica plc: Stuart Paynter, Company Secretary	Tel: [phone]

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people. Further information is available at www.oxb.com

 

END

 

 

TVREAPKLESXNEEF